Replies to post #109211 on Biotech Values

[DewDiligence]

Don't think EXEL would be used for bone-mets-prevention, rather treat those who have developed bone mets already.

Treatment of bone mets is precisely the indication for which Denosumab has a PDUFA date today—see the first group of rows in #msg-51295923.